Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations
{{output}}
Introduction: Proteolysis Targeting Chimeras (PROTACs) represents a groundbreaking advancement in drug discovery and targeted protein degradation. Unlike traditional small-molecule inhibitors, PROTACs leverage the cell's natural... ...
